| Winchester Gardens Health Care Center | |
| 333 Elmwood Avenue, Maplewood, New Jersey 07040 | |
| (973) 762-5050 | |
| Name | Winchester Gardens Health Care Center |
|---|---|
| Location | 333 Elmwood Avenue, Maplewood, New Jersey |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 30 |
| Occupancy Rate | 65.67% |
| Medicare ID (CCN) | 315527 |
| Legal Business Name | Marcus L Ward Home Inc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1265948988 |
| Organization Name | MARCUS L WARD HOME, INC. |
| Doing Business As | WINCHESTER GARDENS |
| Address | 333 Elmwood Ave, Maplewood, NJ 07040 |
| Phone Number | 973-762-5050 |
News Archive
The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.
Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation. For some patients, this may mean successful treatment with radiation alone and avoiding the side effects of chemotherapy.
In a recent customer update, Mark Farrah Associates confirmed that Medicare Advantage membership continues to climb, prior to the 2010 open enrollment season.
An investigational drug is producing powerful responses in patients resistant to Gleevec, the targeted therapy that helps most people diagnosed with chronic myeloid leukemia (CML), an international research team headed by investigators at The University of Texas M. D. Anderson Cancer Center is reporting.
Cosmofrance Inc. introduces Dermasculpt a FDA-approved, FLEXIBLE blunt-tip microcannula for non-bruising & practically painless cosmetic injections.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.
Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation. For some patients, this may mean successful treatment with radiation alone and avoiding the side effects of chemotherapy.
In a recent customer update, Mark Farrah Associates confirmed that Medicare Advantage membership continues to climb, prior to the 2010 open enrollment season.
An investigational drug is producing powerful responses in patients resistant to Gleevec, the targeted therapy that helps most people diagnosed with chronic myeloid leukemia (CML), an international research team headed by investigators at The University of Texas M. D. Anderson Cancer Center is reporting.
Cosmofrance Inc. introduces Dermasculpt a FDA-approved, FLEXIBLE blunt-tip microcannula for non-bruising & practically painless cosmetic injections.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $7036 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|